Fintel reports that on March 25, 2025, Raymond James upgraded their outlook for HealthEquity (NasdaqGS:HQY) from Outperform ...

Raymond James upgraded HealthEquity (HQY) to Strong Buy from Outperform with a price target of $115, down from $120. The firm upgrade the ...

HealthEquity (NASDAQ:HQY – Get Free Report) was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a note issued to investors on Tuesday, MarketBeat.com ...

HealthEquity's Q4 revenue beat estimates, but EPS missed. Raymond James upgraded the stock to Strong Buy, citing long-term growth despite fraud concerns.

HealthEquity, Inc.’s HQY share price has dipped by 17.07%, which has investors questioning if this is right time to buy.

The firm currently has a neutral rating on the stock. A number of other brokerages have also issued reports on HQY. Mizuho assumed coverage on HealthEquity in a report on Wednesday, December 4th.

HealthEquity stock drops after mixed Q4 results despite 18.8% revenue growth. Click here to find out why HQY stock is a Hold.

NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of HealthEquity, ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

Fintel reports that on March 25, 2025, Raymond James upgraded their outlook for HealthEquity (BMV ... VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,744K shares ...